Changes In Manufacturing Pipeline Focus

In Q4, 2019, ISR asked 676 buyers of outsourced manufacturing services about upcoming changes to their pipeline and how it might impact their outsourcing practices. Respondents were asked to indicate their level of agreement with each of the following statements; 42%   agree – strongly agree their organization will increase focus on biomanufacturing, including biosimilars. Combined therapies followed with 33% of respondents mentioning an increased focus therapies like ADCs.